Preclinical development and First-in-human imaging of 89Zr-Daratumumab for CD38 targeted imaging of myeloma

Conclusion: 89Zr-DFO-daratumumab provides successful whole-body PET visualization of myeloma in both a murine myeloma xenograft model and in a first-in-human phase I trial of myeloma patients. This novel PET antibody will be tested for its potential to provide sensitive detection of myeloma, predict the effectiveness of daratumumab therapy, and serve as the basis of theranostic constructs for patients with myeloma. Research support: Leukemia and Lymphoma Society, NIH/NCI Cancer Center Support Grant (P30 CA008748).

Source: Journal of Nuclear Medicine - May 20, 2019 Category: Nuclear Medicine Authors: Ulaner, G., Sobol, N., O'Donoghue, J., Burnazi, E., Staton, K., Weber, W., Lyashchenko, S., Lewis, J., Landgren, C. O. Tags: Oncology, Basic and Translational (Basic Science) I Source Type: research